Cantor Fitzgerald’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Cantor Fitzgerald’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-155,000	Closed	-$2K	–	799
2022 Q3	$2K	Hold	155,000	–	–	﹤0.01%	772
2022 Q2	$1.56M	Hold	155,000	–	–	0.03%	398
2022 Q1	$0	Hold	155,000	–	–	﹤0.01%	461
2021 Q4	$1.55M	Buy	+155,000	New	+$1.57M	0.11%	156

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Cantor Fitzgerald's PBAXU Position: Q4 2022 in Review

Cantor Fitzgerald sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 155,000 shares — an estimated $2K sold.

Cantor Fitzgerald first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $1.56M in Q2 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Cantor Fitzgerald reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Cantor Fitzgerald sold 155,000 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $2K.
Cantor Fitzgerald first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Cantor Fitzgerald's Phoenix Biotech Acquisition Corp. Unit position peaked at $1.56M in Q2 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Cantor Fitzgerald's 13F filing for Q4 2022, filed 14 Feb 2023.